Lipoplatin Formulation Review Article
Joint Authors
Stathopoulos, G. P.
Boulikas, T.
Source
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2011-08-29
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Patented platform technologies have been used for the liposomal encapsulation of cisplatin (Lipoplatin) into tumor-targeted 110 nm (in diameter) nanoparticles.
The molecular mechanisms, preclinical and clinical data concerning lipoplatin, are reviewed here.
Lipoplatin has been successfully administered in three randomized Phase II and III clinical trials.
The clinical data mainly include non-small-cell lung cancer but also pancreatic, breast, and head and neck cancers.
It is anticipated that lipoplatin will replace cisplatin as well as increase its potential applications.
For the first time, a platinum drug has shown superiority to cisplatin, at least in non-squamous non-small-cell lung cancer as reported in a Phase III study which documented a simultaneous lowering of all of the side effects of cisplatin.
American Psychological Association (APA)
Stathopoulos, G. P.& Boulikas, T.. 2011. Lipoplatin Formulation Review Article. Journal of Drug Delivery،Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-482490
Modern Language Association (MLA)
Stathopoulos, G. P.& Boulikas, T.. Lipoplatin Formulation Review Article. Journal of Drug Delivery No. 2012 (2012), pp.1-10.
https://search.emarefa.net/detail/BIM-482490
American Medical Association (AMA)
Stathopoulos, G. P.& Boulikas, T.. Lipoplatin Formulation Review Article. Journal of Drug Delivery. 2011. Vol. 2012, no. 2012, pp.1-10.
https://search.emarefa.net/detail/BIM-482490
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-482490